Jordan's Drugmakers Told To Adapt For WTO Membership

8 June 1997

Jordan's government has asked the country's pharmaceutical industry toadopt to new requirements and standards that will become mandatory when the kingdom is accepted into the World Trade Organization. All industries will be required to do so, with emphasis on intellectual property rights, noted Mohammed Halaiqah, Secretary General of the Ministry of Industry and Trade.

Jordanian drug companies have had major successes by entering many markets, and have acquired recognition in Arab and other countries, he said, but the sector will face strong competition in the world market, and will have to adapt to WTO requirements to guarantee further successes.

Current international economic developments and the trend towards the globalization of the economy present Jordan's industrial sector with major challenges, he told those attending the opening session of a workshop organized by the Jordan Export Development and Commercial Center along with the Jordan University of Science and Technology.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight